Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay.
ALBIA
COVID-19
SARS-CoV-2
luminex
multiplex
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
09
2020
accepted:
26
10
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Despite efforts to develop anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody (Ab) immunoassays, reliable serological methods are still needed. We developed a multiplex addressable laser bead immunoassay (ALBIA) to detect and quantify anti-Spike S1 and nucleocapsid N Abs. Recombinant S1 and N proteins were bound to fluorescent beads (ALBIA-IgG-S1/N). Abs were revealed using class-specific anti-human Ig Abs. The performances of the test were analyzed on 575 serum samples including 192 from SARS-CoV-2 polymerase chain reaction-confirmed patients, 13 from seasonal coronaviruses, 70 from different inflammatory/autoimmune diseases, and 300 from healthy donors. Anti-S1 IgM were detected by monoplex ALBIA-IgM-S1. Comparison with chemiluminescent assays or enzyme-linked immunosorbent assays was performed using commercial tests. Multiplex ALBIA-IgG-S1/N was effective in detecting and quantifying anti-SARS-CoV-2 IgG Abs. Two weeks after first symptoms, sensitivity and specificity were 97.7 and 98.0% (anti-S1), and 100 and 98.7% (anti-N), respectively. Agreement with commercial tests was good to excellent, with a higher sensitivity of ALBIA. ALBIA-IgG-S1/N was positive in 53% of patients up to day 7, and in 75% between days 7 and 13. For ALBIA-IgM-S1, sensitivity and specificity were 74.4 and 98.7%, respectively. Patients in intensive care units had higher IgG Ab levels (Mann-Whitney test,
Identifiants
pubmed: 33324387
doi: 10.3389/fmicb.2020.603931
pmc: PMC7726470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
603931Informations de copyright
Copyright © 2020 Drouot, Hantz, Jouen, Velay, Lamia, Veber, Sibilia, Lotellier, Candon, Alain, Fafi-Kremer and Boyer.
Déclaration de conflit d'intérêts
LD and OB are designated as inventors for the European Patent application EP 20315157.6 filed on April 14, 2020 in the names of Inserm, Université de Rouen and CHU de Rouen and entitled “methods for detecting the presence of coronavirus-specific antibodies in a subject.” The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lab Med. 2020 Sep 1;51(5):e59-e65
pubmed: 32657343
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Medicine (Baltimore). 2005 Jul;84(4):231-49
pubmed: 16010208
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
J Microbiol Immunol Infect. 2020 Jun 5;:
pubmed: 32513617
BMJ. 2020 Jul 3;370:m2655
pubmed: 32620675
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
J Infect Dis. 2020 Jul 6;222(3):362-366
pubmed: 32473021
J Clin Virol. 2020 Jul;128:104413
pubmed: 32403010
Clin Chem. 2020 Jul 1;66(7):875-877
pubmed: 32343775
BMJ. 2020 May 21;369:m2066
pubmed: 32439655
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
J Clin Virol. 2020 Aug;129:104521
pubmed: 32623350
Swiss Med Wkly. 2020 Mar 05;150:w20216
pubmed: 32134111
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
J Am Acad Dermatol. 2020 Nov;83(5):1434-1436
pubmed: 32682889
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
J Clin Virol. 2020 Jul;128:104394
pubmed: 32416599
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334